The potency of GIGA-2339 is claimed to be more than 2,000 times greater than that of plasma-derived HBV treatments.

GIGA-2339 contains more than 1,000 fully human recombinant anti-HBV antibodies and is the first recombinant polyclonal therapeutic in development to treat and ...

Grifols SA’s board recommended that shareholders reject Brookfield Asset Management’s indicative offer, which values the ...

A Spanish court yesterday said it was investigating the US hedge fund Gotham City for allegedly publishing “misleading” ...

A Spanish court yesterday said it was investigating the US hedge fund Gotham City for allegedly publishing “misleading” ...

Grifols (GRFS) informs that its board has held an extraordinary meeting this afternoon “without the intervention of the conflicted board ...

Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative ...

ADRs fell ~6% on Tuesday after its board of directors declined to recommend Brookfield Asset Management's (NYSE:BAM) ...

Grifols said on Tuesday that Canadian investment fund Brookfield's potential 6.45 billion euro ($6.8 billion) offer ...

The global Blood Market is witnessing significant growth due to the increasing demand for body fluids like red blood cells, plasma, and other components for treating chronic medical conditions such as ...

GigaGen announced that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of the first ...